IGF-1 (Insulin-like Growth Factor 1)
IGF-1 (insulin-like growth factor 1) is a naturally occurring hormone-like growth factor involved in cellular growth, repair, and metabolic signalling. It is closely linked to the growth hormone (GH) axis and is commonly measured as a biomarker when clinicians assess endocrine and recovery physiology. Therapeutic use (where considered) requires strict clinical oversight due to its potent biological activity and safety considerations.
What is IGF-1?
IGF-1 (insulin-like growth factor 1) is a peptide growth factor produced primarily in the liver in response to growth hormone (GH), with additional local production in tissues. It plays a role in growth and tissue maintenance by influencing cellular proliferation, differentiation, and repair processes. Clinically, IGF-1 is often discussed as both a signalling molecule and a biomarker that reflects longer-term GH axis activity.
IGF-1 levels can vary with age, nutritional status, sleep quality, training load, liver function, and overall metabolic health. Interpretation is context-dependent and should be evaluated against symptoms, history, and other lab markers.
This information is general and educational. It is not medical advice and is not a substitute for care from a qualified clinician. Any hormone or peptide-related therapy must be clinician-guided and individualised.
How IGF-1 works
IGF-1 binds to the IGF-1 receptor (IGF1R) to trigger intracellular signalling cascades involved in growth and repair. It is part of a regulated endocrine network: GH influences IGF-1 production, and IGF-1 participates in feedback mechanisms that help balance GH axis activity. IGF binding proteins (IGFBPs) also modulate how much IGF-1 is bioavailable to tissues.
In performance and metabolic contexts, clinicians often focus on the relationship between IGF-1, recovery capacity, nutrition, sleep, and training load—rather than treating a lab value in isolation.
Key benefits and areas of clinical interest
IGF-1 is discussed in clinical practice and research in relation to endocrine function, tissue maintenance, and metabolic health. The themes below reflect areas of investigation and clinical discussion, not guaranteed outcomes.
IGF-1 is commonly measured as part of evaluating GH-axis activity, especially when clinicians are assessing symptoms that may relate to recovery, body composition, or broader endocrine function.
Research often links IGF-1 signalling to cellular repair processes and tissue turnover, which is why it is discussed in contexts involving recovery.
IGF-1 pathways are discussed alongside lean mass preservation and metabolic regulation, typically within the context of training, nutrition, and sleep.
IGF-1 is frequently discussed in metabolic and ageing research, but clinical relevance depends on individual health status, goals, and risk profile.
Mechanisms and pathways (high-level)
IGF-1 participates in several signalling pathways involved in growth and repair. High-level mechanisms commonly referenced include:
- IGF-1 receptor (IGF1R) signalling: initiates intracellular cascades associated with growth and repair.
- PI3K/Akt and MAPK pathways: often discussed as downstream routes influencing metabolism, protein synthesis, and cellular adaptation.
- GH → IGF-1 axis regulation: IGF-1 reflects GH-driven production and participates in feedback balance.
- IGF binding proteins (IGFBPs): modulate bioavailability and tissue-level activity.
How clinicians assess suitability
Suitability depends on the clinical question: whether IGF-1 is being assessed as a biomarker, or whether a therapy impacting the GH/IGF axis is being considered. Clinicians evaluate symptoms, history, and objective markers, then determine the most appropriate pathway.
- Symptoms and goals (recovery, body composition, metabolic health)
- Baseline labs (often including endocrine and metabolic markers, where indicated)
- Nutrition, sleep, training load, and overall stress physiology
- Contraindications and risk factors (including past or current malignancy considerations)
Safety and considerations
Because IGF-1 is a potent growth factor, therapies that influence IGF-1 signalling require careful clinical oversight. Risks, contraindications, and monitoring requirements vary depending on the approach, patient history, and baseline risk factors. Clinicians should establish a clear plan for monitoring and follow-up.
If you have a medical condition, are pregnant or breastfeeding, have a history of cancer, or take prescription medications, seek clinician advice before commencing any therapy. Seek urgent medical care for severe or concerning symptoms.
Access pathway
At Revivo, any therapy that may influence the GH/IGF axis is considered only after a clinician-guided assessment. If suitable, your clinician will outline the rationale, expected monitoring, and any required testing to support safe, evidence-based decision-making.
FAQs
Is IGF-1 the same as growth hormone (GH)?
No. GH is a pituitary hormone that helps regulate IGF-1 production (primarily in the liver). IGF-1 is a growth factor that acts downstream, with different regulation and biological effects. Clinicians often assess both within the broader GH axis.
Why do clinicians measure IGF-1?
IGF-1 is commonly used as a marker that reflects longer-term GH axis activity. It can help clinicians evaluate endocrine context alongside symptoms, history, and other laboratory markers.
What can influence IGF-1 levels?
IGF-1 levels can be influenced by age, nutrition and calorie intake, sleep quality, training load, liver function, and overall metabolic health. Interpretation should be individualised rather than based on a single result.
Is IGF-1 therapy suitable for everyone?
No. Any therapy impacting IGF-1 signalling requires careful clinical assessment due to contraindications and risk factors. A clinician will determine suitability and monitoring requirements based on your medical history and goals.